DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CELEBREX

Summary for Tradename: CELEBREX

Patents:4
Applicants:1
NDAs:1
Suppliers: see list19
2013 Sales:$2,237,658,000
drug
patent expirations by year for
 CELEBREX

Pharmacology for Tradename: CELEBREX

Clinical Trials for: CELEBREX

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Status: Active, not recruiting Condition: Recurrent Respiratory Papillomatosis

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
Status: Completed Condition: Lung Cancer

Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine
Status: Completed Condition: Postoperative Pain Management; Total Knee Arthroplasty

Celecoxib as a Chemopreventive Agent in Current and Former Smokers
Status: Completed Condition: Smoking; Prevention

The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children
Status: Not yet recruiting Condition: Pharmacokinetics of Celecoxib in Children

Celecoxib for Pediatric Adenotonsillectomy
Status: Completed Condition: Tonsillectomy; Adenotonsillectomy; Pain, Postoperative

The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
Status: Completed Condition: Ovulation; Luteal Development

Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Status: Recruiting Condition: Hypertension

Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
Status: Not yet recruiting Condition: Knee Osteoarthritis

Safety of Celecoxib in Patients With Crohn's Disease
Status: Terminated Condition: Crohn's Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998Aug 29, 2002RXYes5,466,823*PED<disabled>Y<disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998Aug 29, 2002RXYes5,563,165*PED<disabled>Y<disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998Aug 29, 2002RXYes5,760,068*PED<disabled>Y<disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998Aug 29, 2002RXYesRE44048*PED<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CELEBREX

Drugname Dosage Strength RLD Submissiondate
celecoxibCapsules50 mgCelebrex3/21/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc